FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1490491292> ?p ?o ?g. }

• W1490491292 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAStable-isotope dilution coupled to targeted mass spectrometry (MS), applying selected reaction monitoring (SRM), provides good selectivity, reproducibility, sensitivity, and multiplexing capability rendering it highly suitable for robust, high-throughput and cost-effective verification of cancer biomarker candidates. The ability of SRM-MS to detect and quantify low abundance proteins present in blood plasma/serum at low ng/mL or even lower levels, however, relies on the front-end enrichment through specific affinity reagents (e.g., antibodies). To address this limitation, we have recently developed two antibody-independent, targeted quantification capabilities that enable protein quantification at low or sub ng/mL levels in plasma/serum. The first new capability, PRISM (high-pressure high-resolution separations with intelligent selection and multiplexing)-SRM, uses high resolution basic pH reversed-phase capillary liquid chromatographic (LC) separation with on-line SRM monitoring for the enrichment of target peptides and intelligent selection of target fractions for subsequent LC-SRM analysis that uses very short LC gradient to achieve better sensitivity and improved sample throughput. Application of PRISM-SRM enables highly sensitivity detection of several prostate cancer relevant proteins, e.g., prostate-specific antigen (PSA) and anterior gradient 2 (AGR2) proteins at ∼100 pg/mL level in serum, and distinct TMPRSS2-ERG fusion protein isoforms in cell line and tumor tissue samples. The front-end sample prefractionation often requires a relatively large amount of starting material (e.g., 25 ug in PRISM-SRM analysis) and increased instrument analysis time, and undesired sample losses are often encountered during multistep sample preparation. These can be effectively overcome by the second new capability, long-gradient separations coupled with SRM (LG-SRM). Our results show that LG-SRM enables reliable quantification of plasma proteins at low ng/mL levels in nondepleted human plasma/serum. Comparing to fractionation-based SRM methods, LG-SRM offers better sample throughput, requires minute amounts of starting materials (e.g., ∼4 μg), and provides at least 3-fold greater multiplexing capacity than conventional LC-SRM due to ∼3-fold increase in average peak widths. The complementary SRM strategy encompasses both PRISM-SRM and LG-SRM and is therefore highly attractive for the sensitive and multiplexed quantification of cancer biomarker candidates - PRISM-SRM offers ∼10X higher sensitivity, but LG-SRM requires much less sample and can be readily implemented. It is anticipated that these affinity reagent-free, highly sensitive proteomics measurements made possible by this complementary SRM strategy will bring new biological insights and perspectives to prostate cancer research as well as other cancers.Citation Format: Tujin Shi, Jintang He, Chaochao Wu, Thomas L. Fillmore, Athena A. Schepmoes, Mark Rubin, Javed Siddiqui, John Wei, Arul Chinnaiyan, Alvin Liu, Richard D. Smith, Jacob Kagan, Sudhir Srivastava, Karin D. Rodland, Wei-Jun Qian, Tao Liu, David G. Camp. An antibody-independent, complementary SRM strategy for ultrasensitive and multiplexed quantification of cancer biomarker candidates. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2483. doi:10.1158/1538-7445.AM2014-2483" @default.
• W1490491292 created "2016-06-24" @default.
• W1490491292 creator A5003311852 @default.
• W1490491292 creator A5009003697 @default.
• W1490491292 creator A5015632167 @default.
• W1490491292 creator A5031750008 @default.
• W1490491292 creator A5032251290 @default.
• W1490491292 creator A5032834920 @default.
• W1490491292 creator A5032989837 @default.
• W1490491292 creator A5041343485 @default.
• W1490491292 creator A5043928018 @default.
• W1490491292 creator A5052125746 @default.
• W1490491292 creator A5052184745 @default.
• W1490491292 creator A5064561416 @default.
• W1490491292 creator A5074663242 @default.
• W1490491292 creator A5075235007 @default.
• W1490491292 creator A5077382678 @default.
• W1490491292 creator A5083968353 @default.
• W1490491292 creator A5089737556 @default.
• W1490491292 date "2014-09-30" @default.
• W1490491292 modified "2023-09-26" @default.
• W1490491292 title "Abstract 2483: An antibody-independent, complementary SRM strategy for ultrasensitive and multiplexed quantification of cancer biomarker candidates" @default.
• W1490491292 doi "https://doi.org/10.1158/1538-7445.am2014-2483" @default.
• W1490491292 hasPublicationYear "2014" @default.
• W1490491292 type Work @default.
• W1490491292 sameAs 1490491292 @default.
• W1490491292 citedByCount "0" @default.
• W1490491292 crossrefType "proceedings-article" @default.
• W1490491292 hasAuthorship W1490491292A5003311852 @default.
• W1490491292 hasAuthorship W1490491292A5009003697 @default.
• W1490491292 hasAuthorship W1490491292A5015632167 @default.
• W1490491292 hasAuthorship W1490491292A5031750008 @default.
• W1490491292 hasAuthorship W1490491292A5032251290 @default.
• W1490491292 hasAuthorship W1490491292A5032834920 @default.
• W1490491292 hasAuthorship W1490491292A5032989837 @default.
• W1490491292 hasAuthorship W1490491292A5041343485 @default.
• W1490491292 hasAuthorship W1490491292A5043928018 @default.
• W1490491292 hasAuthorship W1490491292A5052125746 @default.
• W1490491292 hasAuthorship W1490491292A5052184745 @default.
• W1490491292 hasAuthorship W1490491292A5064561416 @default.
• W1490491292 hasAuthorship W1490491292A5074663242 @default.
• W1490491292 hasAuthorship W1490491292A5075235007 @default.
• W1490491292 hasAuthorship W1490491292A5077382678 @default.
• W1490491292 hasAuthorship W1490491292A5083968353 @default.
• W1490491292 hasAuthorship W1490491292A5089737556 @default.
• W1490491292 hasConcept C104317684 @default.
• W1490491292 hasConcept C121608353 @default.
• W1490491292 hasConcept C124535831 @default.
• W1490491292 hasConcept C126322002 @default.
• W1490491292 hasConcept C185592680 @default.
• W1490491292 hasConcept C2780192828 @default.
• W1490491292 hasConcept C2781197716 @default.
• W1490491292 hasConcept C43617362 @default.
• W1490491292 hasConcept C46111723 @default.
• W1490491292 hasConcept C55493867 @default.
• W1490491292 hasConcept C71924100 @default.
• W1490491292 hasConcept C9893847 @default.
• W1490491292 hasConceptScore W1490491292C104317684 @default.
• W1490491292 hasConceptScore W1490491292C121608353 @default.
• W1490491292 hasConceptScore W1490491292C124535831 @default.
• W1490491292 hasConceptScore W1490491292C126322002 @default.
• W1490491292 hasConceptScore W1490491292C185592680 @default.
• W1490491292 hasConceptScore W1490491292C2780192828 @default.
• W1490491292 hasConceptScore W1490491292C2781197716 @default.
• W1490491292 hasConceptScore W1490491292C43617362 @default.
• W1490491292 hasConceptScore W1490491292C46111723 @default.
• W1490491292 hasConceptScore W1490491292C55493867 @default.
• W1490491292 hasConceptScore W1490491292C71924100 @default.
• W1490491292 hasConceptScore W1490491292C9893847 @default.
• W1490491292 hasLocation W14904912921 @default.
• W1490491292 hasOpenAccess W1490491292 @default.
• W1490491292 hasPrimaryLocation W14904912921 @default.
• W1490491292 hasRelatedWork W1967804299 @default.
• W1490491292 hasRelatedWork W1988049110 @default.
• W1490491292 hasRelatedWork W2006048133 @default.
• W1490491292 hasRelatedWork W2044725186 @default.
• W1490491292 hasRelatedWork W2061877464 @default.
• W1490491292 hasRelatedWork W2111865342 @default.
• W1490491292 hasRelatedWork W2418412633 @default.
• W1490491292 hasRelatedWork W2625321431 @default.
• W1490491292 hasRelatedWork W2908892876 @default.
• W1490491292 hasRelatedWork W2968492737 @default.
• W1490491292 hasRelatedWork W3015768899 @default.
• W1490491292 hasRelatedWork W3088054533 @default.
• W1490491292 hasRelatedWork W3093255093 @default.
• W1490491292 hasRelatedWork W3206732964 @default.
• W1490491292 isParatext "false" @default.
• W1490491292 isRetracted "false" @default.
• W1490491292 magId "1490491292" @default.
• W1490491292 workType "article" @default.